Immix Biopharma, Inc..
IMMX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Immix Biopharma, Inc. is a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) to treat cancer and immune-related diseases. Their lead asset, IMX-110, is in Phase 1b/2a clinical trials for advanced soft tissue sarcoma. TSTx technology allows drugs to accumulate at disease sites,...Show More
Better Health for All
0
The provided article, a press release from GlobeNewswire, announces an appointment to the board of directors for Verdafresh, a company focused on packaging technology.
1
It explicitly states that it contains no data relevant to IMMX.US or the 'Better Health for All' value.
2
Therefore, no KPIs can be scored based on the evidence provided.
Fair Money & Economic Opportunity
0
Immix Biopharma, Inc. is a biopharmaceutical company focused on developing treatments for cancer and immune-related diseases. Its core business activities, as evidenced by the provided articles, revolve around clinical trials, regulatory approvals, and drug development. The company does not engage in lending, insurance, or other financial services for consumers.
1
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to Immix Biopharma's operations, aligning with the '0' tier definitions in the rubric for non-financial entities.
Fair Pay & Worker Respect
0
No evidence available to assess Immix Biopharma, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points or quantitative information regarding Immix Biopharma, Inc.'s fair trade and ethical sourcing practices, supply chain audits, incidents of forced or child labor, traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend were found in the provided articles.
1
Honest & Fair Business
-40
Immix Biopharma, Inc. has a formal Code of Business Conduct and Ethics, effective September 10, 2021, which includes a whistleblower policy.
1
This policy encourages employees to report violations to the Chairman of the Audit Committee and explicitly prohibits retaliation for good-faith reports.
2
Violations are to be investigated by the Board or a designated person.
3
The company had one financial restatement in 2020 due to an error in the computation of the Australian Tax Incentive, as disclosed in an October 6, 2021 filing.
4
Kind to Animals
-30
The company, through its involvement with Inductive Bio, is collaborating with Amgen, Cincinnati Children’s Hospital Medical Center, Baylor College of Medicine, and Torch Bio to generate biological datasets from human model systems, which are alternatives to animal testing.
1
It will also work with the U.S. Food and Drug Administration (FDA) to establish a regulatory framework for the models’ use in investigational new drug (IND) applications.
2
No War, No Weapons
0
No evidence available to assess Immix Biopharma, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, quantitative data points or qualitative information regarding Immix Biopharma's environmental performance, emissions, renewable energy use, water management, waste diversion, green building certifications, climate targets, or any other planet-friendly business metrics were found in the provided articles.
1
The articles focus exclusively on clinical trial progress, regulatory approvals, and company operational updates unrelated to sustainability.
2
Respect for Cultures & Communities
0
The provided articles focus on IMMX.US's preclinical research and general clinical trial information.
1
No specific data points or facts related to the company's engagement with local or indigenous communities, cultural impact assessments, community investments, or cultural preservation efforts were found.
2
Safe & Smart Tech
0
No evidence available to assess Immix Biopharma, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Immix Biopharma, Inc. on Zero Waste & Sustainable Products.